1. Alkermes will host a conference call on February 12, 2025. 2. The call will cover Q4 and 2024 year-end financial results. 3. Management will provide financial expectations and updates for 2025. 4. Alkermes focuses on neuroscience with products for various disorders. 5. The company has ongoing clinical developments in neurological disorders.
Upcoming financial results may signal positive growth expectations for 2025, enhancing investor confidence. Similar past earnings calls have often resulted in stock price increases due to positive guidance.
The earnings call is crucial for informing investors about the company’s future direction and health, which directly affects stock price. Positive guidance can strongly impact market perceptions and valuations.
The immediate effect will be observed around the earnings announcement date, influencing short-term investor sentiment. Historically, earnings announcements can lead to rapid price adjustments.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Jamie Constantine
Investor Relations
+1 781 873 2402
SOURCE Alkermes plc